Media stories about Mirna Therapeutics (NASDAQ:SYBX) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mirna Therapeutics earned a news impact score of 0.07 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.1428063953155 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several brokerages recently issued reports on SYBX. Leerink Swann began coverage on Mirna Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $25.00 price target on the stock. ValuEngine lowered Mirna Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Wedbush began coverage on Mirna Therapeutics in a research note on Monday, November 27th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Zacks Investment Research lowered Mirna Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Mirna Therapeutics has an average rating of “Hold” and a consensus price target of $19.67.

Mirna Therapeutics (NASDAQ:SYBX) traded up $0.99 during mid-day trading on Monday, hitting $11.20. The stock had a trading volume of 86,900 shares, compared to its average volume of 13,390. Mirna Therapeutics has a 52 week low of $8.76 and a 52 week high of $23.00.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/04/mirna-therapeutics-sybx-given-daily-news-sentiment-rating-of-0-07.html.

About Mirna Therapeutics

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Insider Buying and Selling by Quarter for Mirna Therapeutics (NASDAQ:SYBX)

Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.